
ASPI — ASP Isotopes Inc. Common Stock
NASDAQ · Basic Materials · Chemicals
$3.80
+$0.02 (+0.53%)
ASP Isotopes Inc. Common Stock (ASPI) is a chemicals company listed on NASDAQ. It is led by Paul Elliot Mann C.F.A., based in 601 Pennsylvania Avenue NW, Washington, DC, United States, 20004, with about 136 employees. ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which selectively ionizes and separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry; Silicon-28, which is used in semiconductors; and Carbon-14 for pharmaceuticals and agrochemicals. In addition, the company develops Zinc-67/68, Nickel-68, and Xenon 129/136 for the nuclear medical industry; Lithium-6, Lithium-7, Uranium-235, Chlorine-37, and Thorium Fluoride for the energy industry; and Germanium-70/72/74. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Latest reported ASPI revenue for 2025-09-30 was $4.9M. Net income was -$12.9M. Revenue was up 308.0% from 2025-06-30 to 2025-09-30. ASPI currently screens at market cap $620.7M.
Use this ASPI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ASPI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ASPI SEC filings page. Lician reads the product cache first so this HTML stays unique to ASP Isotopes Inc. Common Stock even when a live quote feed is slow.
About ASP Isotopes Inc. Common Stock
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which selectively ionizes and separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry; Silicon-28, which is used in semiconductors; and Carbon-14 for pharmaceuticals and agrochemicals. In addition, the company develops Zinc-67/68, Nickel-68, and Xenon 129/136 for the nuclear medical industry; Lithium-6, Lithium-7, Uranium-235, Chlorine-37, and Thorium Fluoride for the energy industry; and Germanium-70/72/74. ASP Isotopes Inc. was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
ASPI Key Statistics
Market Cap
$620.68M
Volume
244,202
Previous Close
$3.89
Day Range
$3.91 – $3.98
EPS
-$0.63
Revenue
$4.14M
Net Income
-$32.42M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+857.0%
Profit Margin
-782.4%
Employees
136
ASPI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $4.14M | $433.03K | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$32.42M | -$16.29M | -$4.95M |
| EPS (Diluted) | -$0.63 | -$0.49 | $0.00 |
Total Assets
$94.35M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$61.90M
Operating Cash Flow
-$16.70M
Free Cash Flow
$0.00
ASP Isotopes Inc. Common Stock Company Information
- President, CEO & Executive Chairman
- Paul Elliot Mann C.F.A.
- Headquarters
- 601 Pennsylvania Avenue NW, Washington, DC, United States, 20004
- Website
- aspisotopes.com
- Phone
- 202 756 2245
- IPO / Founded
- 2022-11-10
- Sector
- Basic Materials
- Industry
- Chemicals